Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer Business Wire
- A Billionaire Saved A Nonprofit. Then Things Got Ugly [Forbes]Forbes
- ImmunityBio, Inc. (NASDAQ: IBRX) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.75. They now have a "neutral" rating on the stock.MarketBeat
- ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious [Seeking Alpha]Seeking Alpha
IBRX
Earnings
- 5/9/24 - Miss
IBRX
Sec Filings
- 8/12/24 - Form 10-Q
- IBRX's page on the SEC website